Stockreport

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Maze Therapeutics, Inc.  (MAZE) 
PDF SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power [Read more]